de Medina M, Ortiz C, Krenc C, Leete J, Vallari D, Hill M, LaRue S, Jimenez M, Anderson W, Schiff E
Department of Medicine, University of Miami School of Medicine, FL.
Am J Kidney Dis. 1992 Dec;20(6):589-91. doi: 10.1016/s0272-6386(12)70224-x.
We tested serum samples from 99 patients undergoing maintenance hemodialysis for hepatitis C virus (HCV) antibodies using a first-generation, licensed anti-HCV enzyme immunoassay (EIA) and a second-generation anti-HCV EIA that detect three gene products c100-3, NS3, and core. Specimens that were repeatedly reactive by either or both screening assays were further evaluated by testing with supplemental EIAs and a dot blot immunoassay. There was 87.9% agreement between the licensed HCV EIA and the HCV EIA second generation. HCV EIA Second Generation detected 10 more positive specimens than HCV EIA, for an increase in detection from 33.3% (33/99) to 43.4% (43/99). We conclude that HCV EIA Second Generation improves detection of HCV infection in hemodialysis patients.
我们使用第一代已获许可的抗丙型肝炎病毒（HCV）酶免疫测定法（EIA）和第二代抗HCV EIA对99例接受维持性血液透析的患者的血清样本进行了丙型肝炎病毒抗体检测，第二代抗HCV EIA可检测三种基因产物c100-3、NS3和核心蛋白。通过任一筛查试验或两项筛查试验反复呈反应性的标本，进一步通过补充EIA和斑点印迹免疫测定法进行检测。已获许可的HCV EIA与第二代HCV EIA之间的一致性为87.9%。第二代HCV EIA比第一代HCV EIA多检测出10份阳性标本，检测率从33.3%（33/99）提高到43.4%（43/99）。我们得出结论，第二代HCV EIA提高了血液透析患者HCV感染的检测率。
